Tisbury Pharmaceuticals
Beverly
About Tisbury Pharmaceuticals
Tisbury Pharmaceuticals discovers, develops, and commercializes therapy to treat primary open angle glaucoma. The company's clinical candidate, R-801, accelerates flow via the trabecular meshwork via redox catalysis and K+-ATP (channel activation). The company was incorporated in 2017 and is based in Beverly, Massachusetts.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $32.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2017)
- Website: tisburypharmaceuticals.com
Industries & Categories
Clinical Trials, Health Care, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/tisbury-pharmaceuticals-144334 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.